COMMUNIQUÉS West-GlobeNewswire

LianBio Announces Completion of Strategic Review
13/02/2024
LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of special cash dividend SHANGHAI, China and PRINCETON, N.J., Feb. 13, [...]
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
13/02/2024
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage [...]
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
13/02/2024
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule [...]
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
13/02/2024
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
13/02/2024
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. [...]
Augmedix Names Tomer Levy as New Senior Vice President of Engineering
13/02/2024
With deep experience in developing operational efficiency and innovation, Levy will be working to aid Augmedix in scaling its products, accelerating product development, and aligning with the needs of large healthcare [...]
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
13/02/2024
The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA ® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to [...]
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
13/02/2024
Announcement Follows Recent Public Offering and Successful Capital Raising Activity KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its [...]
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
13/02/2024
CINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics [...]
RadNet, Inc. Announces Date of its Fourth Quarter 2023 Financial Results Conference Call
13/02/2024
LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
13/02/2024
AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new [...]
Immuron achieves record Travelan® sales
13/02/2024
Highlights: Travelan ® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan ® YTD Jan 2024 sales $2.1 million USA Travelan ® YTD Jan 2024 sales $0.6 million Canadian [...]
Notice to the Annual General Meeting of Orion Corporation
13/02/2024
ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING 13 FEBRUARY 2024 at 12:15 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation of [...]
Orion Group Financial Statement Release January–December 2023
13/02/2024
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1-12/2023 13 FEBRUARY 2024 at 12:00 EET Orion Group Financial Statement Release January–December 2023 Net sales totalled EUR 1,189.7 (January–December 2022: 1,340.6) million [...]
Anocca Appoints Martin Welschof to Board of Directors
13/02/2024
SÖDERTÄLJE, Sweden, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading TCR-T 1 cell therapy company, today announced the appointment of Martin Welschof to its Board of Directors. Martin Welschof is currently CEO of [...]
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
13/02/2024
— Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment — ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a [...]
Myocene Got ISO 13485 Medical-Grade Certification
13/02/2024
LIÈGE, Belgium, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Myocene, the Belgian-based sportstech company, has successfully obtained from a Notified Body the ISO 13485 certification for its quality management system. Myocene is a [...]
PanTera signs agreement with Bayer for the supply of actinium-225
13/02/2024
Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients Mol, Belgium, February 13, 2023: PanTera, the Belgian joint venture created [...]
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
13/02/2024
Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 [...]

Pages